Shares of several vaccine makers including Pfizer and Astrazeneca were down Friday morning following the nomination of Robert ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...

Bavarian Nordic, a maker of the mpox vaccine, on Friday said the incoming Trump administration may present opportunities even ...

Lab mice given the vaccine were able to rapidly clear subsequent chlamydia infections, and were less likely to develop severe ...

Timely vaccinations are essential for protecting children from various communicable diseases, offering up to 90% immunity and ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación ...

After a median follow up of 24.1 months, all 16 patients who received TG4050 ... and machine learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific ...